Athos Capital’s Cidara Therapeutics CDTX Stock Holding History

Athos Capital’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-40,000	Closed	-$8.84M	–	46
2025 Q4	$8.84M	Buy	+40,000	New	+$6.46M	3.39%	8

Athos Capital's CDTX Position: Q1 2026 in Review

Athos Capital sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 40,000 shares — an estimated $8.84M sold.

Athos Capital first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $8.84M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Athos Capital reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Athos Capital sold 40,000 Cidara Therapeutics shares in Q1 2026, an estimated $8.84M.
Athos Capital first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Athos Capital's Cidara Therapeutics position peaked at $8.84M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Athos Capital's 13F filing for Q1 2026, filed 13 May 2026.